Breaking News, Collaborations & Alliances

GSK Buys 10% Stake in German Vaccine Developer CureVac

Companies will collaborate on the research and development mRNA vaccine candidates.

By: Contract Pharma

Contract Pharma Staff

GlaxoSmithKline and CureVac have entered a collaboration for the research, development, manufacturing and commercialization of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform.   GSK will make an equity investment in CureVac of approximately $170 million, representing close to a 10% stake, an upfront cash payment of $137 million and a one...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters